Literature DB >> 7337797

Low red cell activity of pyridoxine (pyridoxamine) phosphate oxidase and glutathione reductase associated with thalassaemia.

J E Clements, B B Anderson, G M Perry.   

Abstract

It was demonstrated in heterozygous alpha 1- and beta-thalassaemia, that the slow rate of red-cell metabolism of vitamin B6, previously shown to be inherited, is regulated by the FMN-dependent pyridoxine (pyridoxamine) phosphate oxidase, as in control subjects. In this study, 60% of the patients with thalassaemia had a low B6 oxidase activity. An inverse correlation with the stimulation of the FAD-dependent glutathione reductase activity by FAD confirmed that red-cell riboflavin status was responsible. The inherited nature and lack of signs of nutritional riboflavin deficiency led to the conclusion that this was the result of a slow rate of red-cell metabolism of riboflavin. Stimulation of glutathione reductase activity by FAD correlated inversely with its basic activity in thalassaemia and control subjects. There was a high incidence of a low activity of this enzyme per red cell in patients with thalassaemia. The possibility that a low activity of glutathione reductase and a slow metabolism of B6 and riboflavin in the red-cell might play a part in the degree of severity of the thalassaemic disease is discussed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7337797

Source DB:  PubMed          Journal:  Biomedicine        ISSN: 0300-0893


  2 in total

1.  Is the flavin-deficient red blood cell common in Maremma, Italy, an important defense against malaria in this area?

Authors:  B B Anderson; M Scattoni; G M Perry; P Galvan; M Giuberti; G Buonocore; C Vullo
Journal:  Am J Hum Genet       Date:  1994-11       Impact factor: 11.025

2.  Inherited glutathione reductase deficiency and Plasmodium falciparum malaria--a case study.

Authors:  Valentina Gallo; Evelin Schwarzer; Stefan Rahlfs; R Heiner Schirmer; Rob van Zwieten; Dirk Roos; Paolo Arese; Katja Becker
Journal:  PLoS One       Date:  2009-10-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.